One Nucleus is always conscious that our member companies are constantly mindful of the need to be international given the nature of the life sciences sector, innovation and the unmet medical needs they seek to address.
Are you a pre-clinical therapeutics start-up?
Stevenage Bioscience Catalyst’s Catalyser is an accelerator designed to help businesses attract investors and partners, and maximise overall chances of commercial success.
The Triple Chasm framework is used to structure the programme via six interactive sessions on the below topics:
Where partnering becomes the science of connection
Participate in the event designed to make every connection meaningful, targeted, and geared towards achieving breakthroughs in biotech.
Through partnership with One Nucleus partners, EBD Group, One Nucleus looks forward to supporting our members again this year at BIO-Europe 2025.
Webcast | 10:00-11:00
President Trump has stated that the next round of US tariffs will apply from 2 April, ‘liberation day’. Our rapid response webcast will assess the blueprint for these tariffs, the impact on UK businesses and the wider business environment.
Meeting Key Performance Indicators
by Tony Jones, CEO, One Nucleus
Read the March edition of our People Pathways newsletter here.
Featuring:
✅One Nucleus upcoming courses
✅South Carolina visit
✅Apprentice opportunity from Domainex
✅Industry news and more...
Oh what a night!
A fantastic array of life science innovators met up at the One Nucleus Annual Awards Dinner in London last night to celebrate their incredible achievements.
Many congratulations to the winners and finalists:
Best Performing Therapeutic Discovery Company of the Year
Winner: AviadoBio
Finalists: Healx, Resolution Therapeutics
Best Performing R&D Platform Development Company of the Year
Winner: Constructive Bio
Finalists: Nuclera, OutSee
The intersection of biotechnology and artificial intelligence has ushered in a new era of possibilities in cellular biology and therapeutic interventions. From advanced gene editing techniques to AI-driven protein engineering, these breakthrough developments are reshaping our approach to biological systems and age-related diseases. The convergence of these fields has opened unprecedented opportunities for precision medicine, regenerative therapies, and the development of novel therapeutic strategies.
Discovery Park has successfully concluded its latest Discovery Spark programme, an intensive business growth catalyst supporting early-stage start-ups. Designed to assist innovators refine their commercial strategies, build investor readiness, and connect with likeminded peers and industry specialists, the programme culminated in pitches from 10 pioneering companies dedicated to improving cancer treatment and patient outcomes.
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that is marked by synovial inflammation, joint destruction, and systemic complication. Aside from causing great physical distress, RA also significantly adds to the socioeconomic burden posed on society.